Stockscreener 앱 받기
1.99
0.00%
0.00
시장 영업 전:
2.04
0.05
+2.51%
전일 마감가:
$1.99
열려 있는:
$1.99
하루 거래량:
528.32K
Relative Volume:
1.14
시가총액:
$209.67M
수익:
$17.91M
순이익/손실:
$-47.66M
주가수익비율:
-4.3775
EPS:
-0.4546
순현금흐름:
$-62.63M
1주 성능:
+8.74%
1개월 성능:
+9.34%
6개월 성능:
-26.57%
1년 성능:
+67.23%
1일 변동 폭
$1.895
$2.0185
1주일 범위
$1.75
$2.15
52주 변동 폭
$1.10
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.99 | 209.67M | 17.91M | -47.66M | -62.63M | -0.4546 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | Oppenheimer | Outperform |
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn
Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn
Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha
PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus
Proqr Therapeutics expands early-stage pipeline - BioWorld News
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World
Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat
ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus
ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - TipRanks
ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com
Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan
ProQR picks rare liver disease for lead drug as more data nears - Stock Titan
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst CallSlideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha
ProQR Therapeutics N.V. Establishes AI Advisory Board - marketscreener.com
ProQR in pact with Ginkgo as part of AI strategy (PRQR:NASDAQ) - Seeking Alpha
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery - TipRanks
ProQR announces partnership with Ginkgo Bioworks and formation of AI advisory board - marketscreener.com
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - The Manila Times
ProQR partners with Ginkgo on AI drug discovery platform - Investing.com
AI deal with Ginkgo boosts ProQR (NASDAQ: PRQR) Axiomer RNA editing plans - Stock Titan
PRQR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROQR THERAPEUTICS NV PB Ratio: 3.11 — Near Median - gurufocus.com
Analysts Set $6.80 Price Target for ProQR Therapeutics - National Today
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn
US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail
Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewswire
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):